When to consider Sancuso
Sancuso® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days.1
Due to its route of administration, SANCUSO may be an alternative for patients on chemotherapy who are unable to take or retain oral antiemetics, including patients who have symptoms or side effects such as oral mucositis or dysphagia, those with gut motility issues, and those receiving concomitant radiation plus chemotherapy treatment1-4,a,b
As SANCUSO can be worn for up to 7 consecutive days depending on the duration of the chemotherapy regimen, it may be an alternative for patients who have experienced breakthrough symptoms in the past as well as forgetful patients who may not remember to take oral antiemetics1,5,6
Are your patients on chemotherapy experiencing diseases or treatment-related complications that make it difficult to take or retain oral antiemetics?
Cancer Types
Head and Neck Cancers7
Chemoradiationb
Chemotherapy
Platinum based (cisplatin)
Microtubular inhibitor (paclitaxel)
Antimetabolite (5-FU)
Breast Cancer8
Chemotherapy
Platinum based (cisplatin)
Microtubular inhibitor (paclitaxel)
Antimetabolite (5-FU)
Lung Cancer9
Chemoradiationb
Chemotherapy
Platinum based (cisplatin, carboplatin)
Gastrointestinal Cancer10
Chemoradiationb
Chemotherapy
Platinum based (cisplatin)
Microtubular inhibitor (paclitaxel)
Antimetabolite (5-FU)
Gynecological Cancer11,12
Chemoradiationb
Chemotherapy
Platiunum based (cisplatin, carboplatin)
Testicular Cancer13
Chemoradiationb
Chemotherapy
Platinum based (cisplatin, carboplatin)
Colorectal Cancer Cancer14,15
Chemoradiationb
Chemotherapy
Platinum based (cisplatin)
Antimetabolite (5-FU)
Possible Chemotherapy Complications
Difficulty Swollowing2
Limited Gut Mobility/absorption3
About Sancuso References
aPatients with cancer who are mechanically compromised include those with oral and/or gastrointestinal impairment associated with chemotherapy, with or without radiation, or tumor burden, who may be unable to take or retain oral antiemetics.2
bSANCUSO is not indicated for radiation-induced nausea and vomiting.1
Verify all references: SANCUSO [package insert]. Bridgewater, NJ: Cumberland Pharmaceuticals, Inc.; 2023. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453-1461. doi:10.1002/cncr.28592. Keller J, Layer P. Intestinal and anorectal motility and functional disorders. Best Pract Res Clin Gastroenterol. 2009;23(3):407-423. doi:10.1016/j.bpg.2009.02.012. Schulmeister L. Granisetron transdermal system: a new option to help prevent chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2009;13(6):711-714. doi:10.1188/09.CJON.711-714. NCCN Clinical
Practice Guidelines in Oncology (NCCN Guidelines®): Antiemesis. National Comprehensive Cancer Network. https://www.nccn.org/ professionals/physician_gls/pdf/antiemesis.pdf. Updated July 20, 2011. Accessed December 18, 2019. Chemo brain. American Cancer Society website. http://www.cancer.org/treatment/treatments-and-side-effects/ physical-side-effects/changes-in-mood-or-thinking/chemo-brain.html.
Updated June 9, 2016. Accessed December 18, 2019. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Head and neck cancers. National Comprehensive Cancer Network. https://www.nccn.org/ professionals/physician_gls/pdf/head-and-neck.pdf. Updated May 30, 2014. Accessed December 18, 2019.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast cancer. National Comprehensive Cancer Network. https:// www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Updated April 1, 2014. Accessed December 18, 2019. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Small cell lung cancer. National Comprehensive Cancer Network. https://www.nccn.org/professionals/ physician_gls/pdf/sclc.pdf.
Updated June 18, 2014. Accessed December 18, 2019. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Gastric cancer. National Comprehensive Cancer Network.
https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Updated May 30, 2014. Accessed December 18, 2019. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Ovarian cancer: including fallopian tube caner and primary peritoneal cancer.
National Comprehensive Cancer Network. https://www.nccn.org/professionals/ physician_gls/pdf/ovarian.pdf. Updated May 9, 2014. Accessed December 18, 2019. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Cervical cancer. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf.
Updated August 7, 2014. Accessed December 18, 2019. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Testicular cancer. National Comprehensive Cancer Network. https://www.nccn.org/ professionals/physician_gls/pdf/testicular.pdf. December 13, 2013.
Accessed December 18, 2019. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Colon cancer. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/ colon.pdf. Updated August 20, 2014. Accessed December 18, 2019.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Rectal cancer. National Comprehensive Cancer Network. https:// www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Updated August 20, 2014. Accessed December 18, 2019. Jensen SB, Pedersen AML, Vissink A, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer. 2010;18(8):1039-1060. doi:10.1007/s00520-010-0827-8. Stacey R, Green JT. Radiation-induced small bowel disease: latest developments and clinical guidance. Ther Adv Chronic Dis. 2014;5(1):15-29. doi:10.1177/2040622313510730. Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction.
Eur J Cancer. 2008;44(8):1105-1115. doi:10.1016/j.ejca.2008.02.028.
SANCUSO® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days.
Sancuso is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the transdermal system.
The most common adverse reaction (≥ 3%) is constipation.
You are encouraged to report suspected adverse reactions to Cumberland Pharmaceuticals Inc. at 1-800-Sancuso or FDA at 1-800-FDA-1088 or www.fda.gov/ medwatch.